The etiology of many neurological diseases affecting the central nervous system (CNS) is
unknown and still needs more effective and specific therapeutic approaches. Gene therapy …

Spinocerebellar ataxias (SCA) comprise a rare, genetic subgroup within the degenerative
ataxias and are dominantly inherited, with up to 48 recognized genetic subtypes. While an …

Although the effects of growth hormone (GH) therapy on spinocerebellar ataxia type 3
(SCA3) have been examined in transgenic SCA3 mice, it still poses a nonnegligible risk of …

Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD) is a progressive motor
disease with no broadly effective treatment. However, most current therapies are based on …

Maintaining proper eye alignment is necessary to generate a cohesive visual image. This
involves the coordination of complex neural networks, which can become impaired by …

A patient-friendly and efficient treatment method for patients with spinocerebellar ataxia type
3 (SCA3) was provided through a nose-to-brain liposomal system. Initially, PGK1 was …

Thiamine (vitamin B1) is a cofactor of fundamental enzymes of cell energetic metabolism; its
deficiency causes disorders affecting both the peripheral and central nervous system …

Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder
that gives rise to motor incoordination and progressive functional disabilities. Although …

Spinocerebellar ataxia type 3 (SCA3) is a genetic neurodegenerative disease for which a
cure is still needed. Growth hormone (GH) therapy has shown positive effects on the …

Abstract Spinocerebellar ataxia type 3 (SCA3) is the most common type of SCA worldwide
caused by abnormal polyglutamine expansion in the coding region of the ataxin-3 gene …